ATHENA: A Phase 3, Open-Label Study Of The Safety And Effectiveness Of Oliceridine (TRV130), A G-Protein Selective Agonist At The µ-Opioid Receptor, In Patients With Moderate To Severe Acute Pain Requiring Parenteral Opioid Therapy.
Sergio D BergeseMarek BrzezinskiGregory B HammerTimothy L BeardPeter H PanSharon E MaceRichard D BerkowitzKristina CochraneLinda WaseHarold S MinkowitzAshraf S HabibPublished in: Journal of pain research (2019)
NCT02656875.